LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dianon Announces Acquisition of UroCor

By Labmedica staff writers
Posted on 20 Nov 2001
In a move to expand its line of cancer diagnostics, Dianon Systems, Inc. (Stratford, CT, USA) has acquired UroCor, Inc. (Oklahoma City, USA) in a stock-for-stock transaction. Dianon provides a full line of anatomic and molecular pathology testing services.

UroCor markets a wide range of products for detecting, diagnosing, and treating prostate cancer, bladder cancer, kidney stones, and other urologic disorders. The company provides diagnostic services to detect major urologic conditions, enhance the accuracy of prognosis, monitor therapy, and identify recurrence.

"This acquisition represents a significant step in our mission to become the leader in cancer diagnostics through expert pathology, clinical, and genomic services,” said Kevin C. Johnson, chairman, president, and CEO of Dianon Systems.





Related Links:
UroCor
Dianon
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more